Human plasma kallikrein inhibitors
US11230530B2 · kind B2 · utility
5Cited by
8References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2020 |
| Grant date | Jan 25, 2022 |
| Priority date | — |
| Expiry date | Apr 10, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of formula I:as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.